Profile Picture
  • All
  • Search
  • Local Search
  • Images
  • Videos
    • Shorts
  • Maps
  • More
    • News
    • Shopping
    • Flights
    • Travel
  • Notebook
Report an inappropriate content
Please select one of the options below.
  • Length
    AllShort (less than 5 minutes)Medium (5-20 minutes)Long (more than 20 minutes)
  • Date
    AllPast 24 hoursPast weekPast monthPast year
  • Resolution
    AllLower than 360p360p or higher480p or higher720p or higher1080p or higher
  • Source
    All
    Dailymotion
    Vimeo
    Metacafe
    Hulu
    VEVO
    Myspace
    MTV
    CBS
    Fox
    CNN
    MSN
  • Price
    AllFreePaid
  • Clear filters
  • SafeSearch:
  • Moderate
    StrictModerate (default)Off
Filter
Pembrolizumab: A Breakthrough in Treating Recurrent DDLPS
2:31
Pembrolizumab: A Breakthrough in Treating Recurrent DDLPS
5 hours ago
YouTubeThe Great Connection
Pembrolizumab Achieves Pathological Complete Response in Recurrent Dedifferentiated Liposarcoma
9:19
Pembrolizumab Achieves Pathological Complete Response i…
7 hours ago
YouTubePulse Wave
Pembrolizumab Achieved pCR in Patient With Recurrent DDLPS
6:59
Pembrolizumab Achieved pCR in Patient With Recurrent DDLPS
8 hours ago
YouTubeVoices Without Borders
Case Report: Pembrolizumab Induces pCR in Recurrent DDLPS with High TMB
Case Report: Pembrolizumab Induces pCR in Recurrent DDLPS …
7 hours ago
YouTubePop Culture Files
Pembrolizumab Sparks Complete Response in Rare DDLPS Case: What This Means for Immunotherapy
1:04
Pembrolizumab Sparks Complete Response in Rare DDLPS Case: W…
6 hours ago
YouTubeOne Planet Channel
Vietnam Approves Russian-Made Immunotherapy for 14 C4ncer Types
0:06
Vietnam Approves Russian-Made Immunotherapy for 14 C4ncer Types
4.1K views1 week ago
YouTube6Snews
Immune Checkpoint Inhibitors: A Potential Breakthrough for Dedifferentiated Liposarcoma Patients
Immune Checkpoint Inhibitors: A Potential Breakthrough for Dediffe…
8 hours ago
YouTubeAny Time Any Topic
See more videos
Static thumbnail place holder
More like this
Feedback
  • Privacy
  • Terms